{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:13:53Z","timestamp":1781712833129,"version":"3.54.5"},"reference-count":37,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T00:00:00Z","timestamp":1723593600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.urolonc.2024.05.026","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T21:32:28Z","timestamp":1720819948000},"page":"447.e1-447.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer"],"prefix":"10.1016","volume":"42","author":[{"given":"Mark A.","family":"Preston","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Ebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1343-8314","authenticated-orcid":false,"given":"Priyanka","family":"Bobbili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-820X","authenticated-orcid":false,"given":"Raj","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5035-6687","authenticated-orcid":false,"given":"Mei Sheng","family":"Duh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dufour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia K.","family":"Morgans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2024.05.026_bib0001","doi-asserted-by":"crossref","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023;73(1):17\u201348. doi: https:\/\/doi.org\/10.3322\/caac.21763.","DOI":"10.3322\/caac.21763"},{"issue":"6","key":"10.1016\/j.urolonc.2024.05.026_bib0002","first-page":"e26209","article-title":"Cardiovascular effects of androgen deprivation therapy in prostate cancer patients: a systematic review","volume":"14","author":"Kakarla","year":"2022","journal-title":"Cureus"},{"key":"10.1016\/j.urolonc.2024.05.026_bib0003","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8145173","article-title":"Causes of death after prostate cancer diagnosis: a population-based study","volume":"2022","author":"Guo","year":"2022","journal-title":"Oxid Med Cell Longev"},{"issue":"6","key":"10.1016\/j.urolonc.2024.05.026_bib0004","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","article-title":"Updates to advanced prostate cancer: AUA\/SUO guideline (2023)","volume":"209","author":"Lowrance","year":"2023","journal-title":"J Urol"},{"issue":"Suppl 1","key":"10.1016\/j.urolonc.2024.05.026_bib0005","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.4103\/ijc.IJC_65_21","article-title":"Gonadotropin-releasing hormone agonists in prostate cancer: a comparative review of efficacy and safety","volume":"59","author":"Raja","year":"2022","journal-title":"Indian J Cancer"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.026_bib0006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/pcan.2012.25","article-title":"New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists","volume":"16","author":"Shore","year":"2013","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"10.1016\/j.urolonc.2024.05.026_bib0007","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/s41585-020-0335-7","article-title":"Intermittent versus continuous androgen deprivation therapy for advanced prostate cancer","volume":"17","author":"Perera","year":"2020","journal-title":"Nat Rev Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.05.026_bib0008","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.urology.2013.01.078","article-title":"Efficacy of intermittent androgen deprivation therapy vs conventional continuous androgen deprivation therapy for advanced prostate cancer: a meta-analysis","volume":"82","author":"Tsai","year":"2013","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.urolonc.2024.05.026_bib0009","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4103\/0970-1591.52907","article-title":"Adverse effects of androgen deprivation therapy in prostate cancer: current management issues","volume":"25","author":"Bagrodia","year":"2009","journal-title":"Indian J Urol"},{"issue":"Suppl 2","key":"10.1016\/j.urolonc.2024.05.026_bib0010","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.3747\/co.v17i0.711","article-title":"Intermittent versus continuous androgen suppression therapy: do we have consensus yet?","volume":"17","author":"Buchan","year":"2010","journal-title":"Curr Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2024.05.026_bib0011","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.3390\/cancers15082316","article-title":"Review of cardiovascular risk of androgen deprivation therapy and the influence of race in men with prostate cancer","volume":"15","author":"Fradin","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"27","key":"10.1016\/j.urolonc.2024.05.026_bib0012","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer","volume":"24","author":"Keating","year":"2006","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.urolonc.2024.05.026_bib0013","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1200\/JCO.2014.59.1792","article-title":"Risk and timing of cardiovascular disease after androgen-deprivation therapy in men with prostate cancer","volume":"33","author":"O'Farrell","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2024.05.026_bib0014","doi-asserted-by":"crossref","DOI":"10.1161\/HCG.0000000000000082","article-title":"Impact of hormonal therapies for treatment of hormone-dependent cancers (breast and prostate) on the cardiovascular system: effects and modifications: a scientific statement from the American Heart Association","volume":"14","author":"Okwuosa","year":"2021","journal-title":"Circ Genom Precis Med"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.026_bib0015","first-page":"1","article-title":"Intermittent androgen deprivation therapy: redefining the standard of care?","volume":"12","author":"Shore","year":"2010","journal-title":"Rev Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.026_bib0016","first-page":"14","article-title":"Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions","volume":"11","author":"Paller","year":"2013","journal-title":"Clin Adv Hematol Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2024.05.026_bib0017","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.juro.2016.12.022","article-title":"Risks of serious toxicities from intermittent versus continuous androgen deprivation therapy for advanced prostate cancer: a population based study","volume":"197","author":"Tsai","year":"2017","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.05.026_bib0018","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1001\/jamaoncol.2015.4655","article-title":"Adverse health events following intermittent and continuous androgen deprivation in patients with metastatic prostate cancer","volume":"2","author":"Hershman","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2024.05.026_bib0019","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/pcan.2016.48","article-title":"A meta-analysis of cardiovascular events in intermittent androgen-deprivation therapy versus continuous androgen-deprivation therapy for prostate cancer patients","volume":"19","author":"Jin","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"4","key":"10.1016\/j.urolonc.2024.05.026_bib0020","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/JU.0000000000001876","article-title":"Real-world practice patterns and predictors of continuous versus intermittent androgen deprivation therapy use for prostate cancer in older men","volume":"206","author":"Cheung","year":"2021","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2024.05.026_bib0021","unstructured":"National Cancer Institute. (2019) SEER-Medicare: brief description of the SEER-Medicare database. Available at: https:\/\/healthcaredelivery.cancer.gov\/seermedicare\/overview\/(accessed June 20, 2023)."},{"issue":"4","key":"10.1016\/j.urolonc.2024.05.026_bib0022","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.urpr.2014.11.001","article-title":"Adoption of intermittent androgen deprivation therapy for advanced prostate cancer: a population based study in American Urology Practice","volume":"2","author":"Tsai","year":"2015","journal-title":"Urol Pract"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.026_bib0023","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/ckj\/sfab158","article-title":"An introduction to inverse probability of treatment weighting in observational research","volume":"15","author":"Chesnaye","year":"2022","journal-title":"Clin Kidney J"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.026_bib0024","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0378-5122(01)00270-5","article-title":"The mechanisms of thrombotic risk induced by hormone replacement therapy","volume":"40","author":"Cano","year":"2001","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.026_bib0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.thromres.2007.03.008","article-title":"Experimental arterial thrombosis regulated by androgen and its receptor via modulation of platelet activation","volume":"121","author":"Li","year":"2007","journal-title":"Thromb Res"},{"issue":"1\u20132","key":"10.1016\/j.urolonc.2024.05.026_bib0026","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5489\/cuaj.3936","article-title":"Effects of androgen-deprivation therapy on hypercoagulability in prostate cancer patients: a prospective, longitudinal study","volume":"11","author":"Kaur","year":"2017","journal-title":"Can Urol Assoc J"},{"issue":"5","key":"10.1016\/j.urolonc.2024.05.026_bib0027","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.urolonc.2017.01.025","article-title":"The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy","volume":"35","author":"Crawford","year":"2017","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2024.05.026_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188383","article-title":"Cardiovascular risks and toxicity - the Achilles heel of androgen deprivation therapy in prostate cancer patients","volume":"1874","author":"Muniyan","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"3","key":"10.1016\/j.urolonc.2024.05.026_bib0029","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.urolonc.2024.05.026_bib0030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.6004\/jnccn.2022.7083","article-title":"Androgen deprivation therapy and risk of cardiovascular disease in patients with prostate cancer based on existence of cardiovascular risk","volume":"21","author":"Dragomir","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.urolonc.2024.05.026_bib0031","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1097\/JU.0000000000000384","article-title":"Cardiovascular morbidity in a randomized trial comparing GnRH agonist and GnRH antagonist among patients with advanced prostate cancer and preexisting cardiovascular disease","volume":"202","author":"Margel","year":"2019","journal-title":"J Urol"},{"issue":"10","key":"10.1016\/j.urolonc.2024.05.026_bib0032","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.30587","article-title":"Real-world cardiovascular outcomes associated with degarelix vs leuprolide for prostate cancer treatment","volume":"4","author":"Wallach","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"6_suppl","key":"10.1016\/j.urolonc.2024.05.026_bib0033","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1200\/JCO.2022.40.6_suppl.046","article-title":"Real-world analyses of major adverse cardiovascular event risk by drug class after initiation of androgen deprivation therapy","volume":"40","author":"Crawford","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.urolonc.2024.05.026_bib0034","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.1002\/ijc.33397","article-title":"Risk of cardiovascular disease following gonadotropin-releasing hormone agonists vs antagonists in prostate cancer: real-world evidence from five databases","volume":"148","author":"George","year":"2021","journal-title":"Int J Cancer"},{"issue":"16","key":"10.1016\/j.urolonc.2024.05.026_bib0035","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: The primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.urolonc.2024.05.026_bib0036","unstructured":"U.S. Food & Drug Administration. (2020). FDA approves relugolix for advanced prostate cancer. Available at:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-relugolix-advanced-prostate-cancer#:\u223c:text=On%20December%2 Available at: 018%2C%202020%2C%20the,patients%20with%20 advanced %20prostate %20cancer. (accessed July 13, 2023)."},{"issue":"23","key":"10.1016\/j.urolonc.2024.05.026_bib0037","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392400499X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107814392400499X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T08:33:31Z","timestamp":1731746011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107814392400499X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S107814392400499X"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.05.026","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of cardiovascular events following intermittent and continuous androgen deprivation therapy in patients with nonmetastatic prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2024.05.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}